Proactive Investors - Run By Investors For Investors

Thursday's followed - global share sell off and contrary Tesla

The turmoil in global equities and the oil price slide continues....and in other news...
Thursday's followed - global share sell off and contrary Tesla
Shares in the tech/ automobile firm added over 6% in New York today and surged after hours

The turmoil in global equities and the oil price slide  continues - with West Texas Intermediate -  now hovering around the US$27 mark - below what was called the last "pyschological" cut-off of US$30.

It is a topsy turvy world indeed currently, so no surprise perhaps then, that  luxury car maker Tesla (NASDAQ:TSLA) - and Elon Musk baby -  throws out another curved ball today.

Shares in the tech/ automobile firm added over 6% in New York and surged after hours after it posted quarterly earnings, which sent out a myriad of mixed fumes (although of course it didn't, cos it's electric vehicles).

On the one hand, the quarterly figures were disappointing, and less than analysts had hoped,  with an adjusted loss of 87 cents per share on US$1.75bln in sales.

But on the other there was positive news on production targets for this year and for those that follow the firm closely, exciting news that the new Model 3 vehicle will go on sale from March 31.

This is the first "moderately" priced electric car, which some  may be surprised to hear has a starting price of US$35,000.

Tesla also said it expects to ship 80,000 to 90,000 Model S and Model X cars in 2016, beating forecasts that the company would only ship about 76,000.

So what else was going on?

Junior biotech Neurotrope (OTCMKTS:NTRP) shares edged up 2.5% as it had some news on a potential treatment for devastating Alzheimer’s disease.

First patients have been dosed in its phase 2b clinical trial of lead candidate Bryostatin-1 for the advanced form of the disease.

The company expects to report three month interim data during the first quarter of 2017 with complete six month data set expected during the first half of 2017.

RISERS

Tesla Motors (NASDAQ:TSLA) accelerates 6.5% to US$152.96 atfre the automaker gave a forecast for deliveries of its Model X that topped analyst estimates, and also said it expected to be profitable this year.

Expedia (NASDAQ:EXPE) jumps 8.2% to US$102.05 after giving an upbeat 2016 profit forecast.

Tripadvisor (NASDAQ:TRIP) soars 15.6% to US$62.85 after reporting adjusted quarterly profit and revenue above estimates. It benefited from higher ad sales and an increase in subscriptions.

FALLERS

Monster Worldwide (NYSE:MWW) cascades 34% to US$2.82 as it reported a decline in sales for its fourth quarter, which were worse than analysts had feared.

Twitter drops (NYSE:TWTR) 4.3% to US$14.33 after the key metric of monthly average users fell, and the company gave current quarter revenue guidance that falls below Street forecasts.

SolarCity (NASDAQ:SCTY) extends Wednesdays to fall a further 7.8% to US$17.18 after chief financial officer Brad Buss resigned, replaced by SolarCity President Tanguy Serra, in wake of poorly received 2015 earnings.

 

 

View full NTRP profile View Profile

Neurotrope Timeline

Related Articles

pills
January 15 2019
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
blood samples in test tubes
October 25 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies
Alliance
April 05 2019
Chief executive Peter Butterfield said the company has started 2019 well-positioned for growth after a strong performance in 2018.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use